Episode Details
Back to EpisodesHER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025
Episode 608
Published 6 months ago
Description
Drs. Dizon and Campos discuss how new antibody drug conjugates like trastuzumab deruxtecan are transforming treatment options for HER2+ gynecological cancers, showing promising results even in patients with low HER2 expression. They shared impressive clinical trial successes while emphasizing the importance of ongoing research into treatment sequencing and patient safety.